Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irbesartan effects on insulin-induced microvascular responses in essential hypertension
NL-OMON24297Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Mar 2008
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label trial of irbesartan, felodipine, human insulin and Angiotensin II in essential hypertension and hypertension (HTN) (6 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Functional recruitment of capillaries in the skin and AT1-receptor blockade after a single oral dose of irbesartan. Started Mar 2008; status: active, not recruiting.
02
Drugs
irbesartanfelodipinehuman insulinAngiotensin II
03
Conditions
essential hypertensionhypertension (HTN)
Beyond the preview
Go deeper on NL-OMON24297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24297.